Company news

Beijing Konruns Pharmaceutical Co., Ltd. Class A (SSE:603590) news

Beijing Konruns Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "Beijing Konruns Pharmaceutical Co., Ltd."Announcement…

Beijing Konruns Pharmaceutical Co., Ltd. Class A (SSE:603590) news

Press releases & updates

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on the Arbitration Result

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Results of the Initial Grant under the 2026 Restricted Share Incentive Plan

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Obtaining New Veterinary Drug Registration Certificate

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Release of Trading Restrictions and Listing of Shares for the 3rd Lock-up Period of the Initial Grant under the 2023 Restricted Share Incentive Plan

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Lifting of Restrictions and Listing of Shares for the Second Lock-up Period of Reserved Grant under the 2023 Restricted Share Incentive Plan

"Beijing Konruns Pharmaceutical Co., Ltd."Semi-annual Report for 2026

"Beijing Konruns Pharmaceutical Co., Ltd."Self-inspection Report on Trading in the Company's Shares by Insiders with Access to Inside Information in Relation to the 2026 Restricted Share Incentive Plan

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Redemption of Cash Management Products Purchased with Certain Idle Raised Funds

"Beijing Konruns Pharmaceutical Co., Ltd."Review Opinion and Statement on the Public Disclosure of the List of Participants for the Initial Grant under the Company's 2026 Restricted Stock Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on the Change in the Company's Registered Capital

"Beijing Konruns Pharmaceutical Co., Ltd."Announcement on Implementation of Dividend Distribution for 2025

Announcement on Achieving Conditions for Lifting Sales Restrictions in 3rd Lifting Period of Initially Granted Part and 2nd Lifting Period of Reserved Granted Part under the 2023 Restricted Stock Incentive Plan

Announcement on Adjusting Total Cash Dividends for 2025 Annual Profit Distribution

Announcement on Progress in Repurchasing 1% Shares through Call Auction and Repurchasing Shares

Announcement on Progress in Repurchasing Shares

Announcement on presentation of KC1036 for the treatment of advanced thymic tumors in the form of a poster at the 2026 ASCO Annual Meeting

Announcement on Redemption at Maturity of Partial Idle Raised Funds Used for Cash Management

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on the Acceptance of the Marketing Authorization Application for Jincaopian Tablets

Announcement on Presentation of Preclinical Study Data of Innovative Drugs KC1086 and KC1101 at the AACR Annual Meeting 2026

Announcement on the Implementation of Directors’ and Senior Management Members’ Remuneration in 2025 and the Plan for 2026

Announcement on Approval by CDE for the Key Phase III Clinical Study of KC1036 as a Second-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma

Announcement on Canceling Special Accounts for Partial Raised Funds and Special Settlement Accounts for Cash Management

Announcement on KC1036 Obtaining CDE Approval for Pivotal Phase III Clinical Study in Advanced Thymic Carcinoma

Announcement on the Receipt of Clinical Trial Notification for KC1036 Combined with PD-1/PD-L1 Antibody in the Treatment of Advanced Solid Tumors

Announcement on Using Partial Idle Raised Funds for Cash Management and Redemption

Earnings Preannouncement for 2025

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Announcement on Election of Employee Director

Announcement on FDA Approval for Clinical Trials of KC1086 Project

Announcement on Company Re-certified as High-tech Enterprise

Announcement on Resolutions of the 18th Meeting of the 4th Board of Supervisors

Announcement on Implementing Repurchase and Cancellation under 2023 Restricted Stock Incentive Plan

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Result of Shareholding Reduction by Shareholder

Report for Q3 2025

Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Not Subject to Sales Restrictions Concerning Share Repurchase

Announcement on Repurchasing Shares through Call Auction for the 1st Time and Progress in Share Repurchase

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Announcement on Resolutions of the 16th Meeting of the 4th Board of Supervisors

Announcement on Convening the 2025 Semi-annual Performance Briefing

Announcement on Release of Pledge of Partial Shares of Controlling Shareholders

Announcement on Results of Shareholding Reduction by Senior Management Members

Announcement on Receipt of Clinical Trial Approval Notice for KC1036 in Combination with PD-1 Antibody and Platinum-based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Announcement on Lifting Sales Restrictions and Listing for Circulation in the 2nd Restriction Period for the 1st Grant under 2023 Restricted Stock Incentive Plan

Pilot Project of the Center for Drug Evaluation

Announcement on Abnormal Fluctuations in Stock Trading

Announcement on Lifting Sales Restrictions in the 1st Sales Restriction Period of Reserved Grant under the 2023 Restricted Stock Incentive Plan and Listing of Shares